# Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

> **NCT06961357** · PHASE1,PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 36 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Interleukin-2
- **DRUG:** TIL Product

## Key facts

- **NCT ID:** NCT06961357
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2029-05
- **Final completion:** 2030-05
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06961357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06961357, "Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT06961357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*